I-Menthol Veterinary Grade API (model designations IM-VET-100 for solid oral and premix applications, IM-VET-200 for injectable/low-endotoxin applications, and IM-VET-M100 for micronised suspension grades) is supplied as colourless crystals or white crystalline powder. The substance is described in pharmacopoeial monographs as levomenthol, CAS 2216-51-5, molecular formula C₁₀H₂₀O, molecular weight 156.27 g/mol. It is produced under veterinary GMP conditions for formulation into tablets, injections, capsules, powders, granules, premix, and oral or topical solutions. The final crystallisation uses a stereochemically controlled route with class 3 solvents controlled under ICH Q3C; batches are processed in 50–500 kg glass-lined crystallisers, centrifuged, and vacuum-dried at 30–35 °C under −0.08 MPa to limit sublimation. Storage is specified below 30 °C in sealed aluminium-lined fibre drums because the melting range of 41–44 °C can permit solid-state sintering during warehouse temperature excursions above 28 °C.

How Does Enantiomeric Purity Influence Pharmacopoeial Compliance and Product Difference?

Chiral purity separates I-Menthol Veterinary Grade API from racemic menthol and technical terpene fractions. The specific optical rotation measured at 20 °C in ethanol at a concentration of 10 g/100 mL is controlled between −48° and −51° by Ph. Eur. 2.2.7. Racemic menthol shows negligible net rotation and contains approximately equimolar D-menthol, while I-Menthol is specified with enantiomeric excess ≥99.0%. The release method uses chiral gas chromatography on a β-cyclodextrin stationary phase; system suitability requires resolution between D-menthol and L-menthol not less than 1.5 and injection repeatability ≤1.0% RSD. Related substances by GC-FID are limited to total ≤1.0%, with menthone, isomenthone, neomenthol, and D-neomenthol individually controlled at ≤0.30% and any unspecified impurity at ≤0.20%. Technical menthol grades by comparison can contain 3–8% total terpene-related impurities and residual hydrocarbons from catalytic hydrogenation. This difference is significant in veterinary oral powders because D-menthol has different sensory receptor activity and can affect feed palatability and dose uniformity in taste-masked premix systems.

Direct compression of IM-VET-100 into tablets and capsules requires particle size control because the crystalline surface is waxy and deforms plastically under compaction. The granular grade is controlled to D90 ≤800 µm and D10 ≥100 µm; powder flow by Ph. Eur. 2.9.36 or USP <1174> is typically associated with Hausner ratio 1.25–1.35. A Hausner ratio above 1.45 after storage indicates caking, and production-scale blending has shown agglomerate formation when dry blends are held for more than 24 h in unjacketed bin blenders at ambient temperatures above 28 °C. Jacketed blending at 18–22 °C, pre-sieving through 1.0 mm mesh, and delayed lubrication with magnesium stearate 0.5% w/w reduce weight variation. Capsule mix uniformity is assessed against USP <905> acceptance value ≤15. For aqueous dispersions and suspension premix, micronised IM-VET-M100 with D90 ≤50 µm is used; dry screening is performed at relative humidity 40–55% to reduce electrostatic adhesion to stainless steel contact surfaces.

When Injectable Formulations Require Cold Aseptic Handling Rather Than Terminal Steam Sterilisation

Injectable use of I-Menthol is constrained by its volatility and low melting range. Terminal steam sterilisation at 121 °C for 15 min is unsuitable in open or semi-closed systems because API loss to headspace and condensate can reach 2–4% of label claim. The injectable grade IM-VET-200 is therefore processed by aseptic dissolution in ethanol, propylene glycol, or medium-chain triglycerides and filtered through a sterile 0.22 µm polyethersulfone or PVDF filter validated for bacterial retention under ASTM F838-20. Differential pressure across the sterilising filter is maintained below 0.8 bar at 25 °C to avoid supersaturation and crystallisation in the filter housing. The injectable grade carries a bacterial endotoxin limit of ≤0.25 EU/mg by Ph. Eur. 2.6.14 or USP <85>, and bioburden before filtration is controlled to ≤10 CFU/100 mL. Water is a poor solvent for I-Menthol; solutions at 1.0 g/L in 30% v/v ethanol-propylene glycol remain clear at 2–8 °C, but dilution below 15% v/v organic co-solvent has produced fine crystals after 48 h under refrigeration. Any aqueous dilution for injection must therefore be subjected to subvisible particulate testing by USP <787> or USP <788> and physical stability confirmation before batch release.

Thermal analysis by differential scanning calorimetry at 10 K/min under nitrogen using ISO 11357-1 shows a single melting endotherm onset at 41–43 °C. A shoulder below 33 °C or a second endotherm above 36 °C in routine release has been linked to polymorphic contamination or residual solvent. X-ray powder diffraction is used to confirm stable crystal-form identity because compaction can introduce lattice disorder without chemical degradation. Residual solvents are determined by headspace gas chromatography using Ph. Eur. 2.4.24 and USP <467>. The final crystallisation solvent system is limited to ethanol and isopropanol; class 1 and class 2 solvents are not used. Typical release data show ethanol ≤5000 ppm, isopropanol ≤5000 ppm, and total class 3 solvents ≤5000 ppm.

Particle Size, Premix Flow, and Solution Stability Boundaries

Premix and granule production uses the granular IM-VET-100 grade. In ribbon mixer trials at 200 kg scale, addition of 5.0 kg API per tonne to a carrier of wheat middlings, calcium carbonate, and dextrose produced assay coefficient of variation ≤5.0% after 15 min at 30 rpm, provided the API was pre-sieved through 1.0 mm mesh. Direct addition without pre-sieving produced menthol-rich clusters in dead zones and coefficient of variation above 8.0%. Wet granulation with a purely aqueous binder is limited because I-Menthol is practically insoluble in water. Hydroalcoholic granulation using ethanol 30–50% v/v or an aqueous binder containing HPMC 2% w/v improves distribution, but drying must be performed below 35 °C. Vacuum drying at −0.08 MPa and 30 °C or fluid-bed drying with inlet air ≤28 °C is preferred to prevent sublimation losses. Oral solutions are prepared by dissolving I-Menthol in ethanol 96% and propylene glycol before dilution with water. A typical stock vehicle contains ethanol 10–30% v/v, propylene glycol 20–40% v/v, and water to volume, with API loading of 0.5–5.0 g/L. Below 15% v/v organic co-solvent, refrigerated batches have shown crystalline precipitation after 48 h, so physical stability is confirmed by laser diffraction and visual inspection before packaging.

Micronisation of IM-VET-M100 must be performed under inert gas or with jacket cooling at 15–20 °C because the material softens near 35 °C and begins to adhere to mill internals. The API is incompatible with strong oxidising agents, acid chlorides, and hypochlorite disinfectants, which can convert menthol to menthone or chlorinated degradation products. For finished feed premix applications, production-scale palatability observations in swine and calves have indicated reduced intake when total menthol exceeds 100 mg/kg complete feed; peer-reviewed published dose-response data for this specific species threshold remains limited.